Raymond James initiated coverage of Aquestive Therapeutics with an Outperform rating and $7 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
- Aquestive Therapeutics 16.667M share Spot Secondary priced at $4.50
- Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
- Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
- Aquestive Therapeutics announces common stock offering, no amount given